MX2017002596A - Composiciones y métodos farmacéuticos. - Google Patents

Composiciones y métodos farmacéuticos.

Info

Publication number
MX2017002596A
MX2017002596A MX2017002596A MX2017002596A MX2017002596A MX 2017002596 A MX2017002596 A MX 2017002596A MX 2017002596 A MX2017002596 A MX 2017002596A MX 2017002596 A MX2017002596 A MX 2017002596A MX 2017002596 A MX2017002596 A MX 2017002596A
Authority
MX
Mexico
Prior art keywords
dodecahydrocyclopenta
phenanthren
oxo
dimethyl
release profile
Prior art date
Application number
MX2017002596A
Other languages
English (en)
Inventor
Giliyar Chandrashekar
Frank Joel
Venkateshwaran Srinivasan
Kumar Nachaegari Satish
Chidambaram Nachiappan
V Patel Mahesh
Original Assignee
Lipocine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipocine Inc filed Critical Lipocine Inc
Publication of MX2017002596A publication Critical patent/MX2017002596A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones y formas de dosificación que permiten alta carga de fármaco para fármacos altamente lipofilicos, mientras mantienen excelente bidisponibilidad oral. Las composiciones farmacéuticas y formas de dosificación unitaria descritas en la presente pueden reducir la carga de la píldora para fármacos hidrofóbicos como tridecanoato de (8R, 9S, 10R, 13S, 14S, 17S) - 10, 13-dimetil-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahidrociclope nta [a] fenantren-17-ilo o tetradecanoato de (8R,9S,10R,13S,14S,17 S,)-10,13-dimetil-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahidro ciclopenta [a] fenantren-17-ilo, y pueden ser formuladas a cargas de fármaco ventajosas (por ejemplo, más de 23%) mientras porporcionan biodisponibilidad adecuada (por ejemplo, capaz de tratar un macho hipogonadal con menos de 10 formas de dosificación unitaria por día) que permite la reducción en la carga de la píldora y por consiguiente, adherencia o cumplimiento mejorado del paciente. Adicionalmente, la composición (por ejemplo, forma de dosificación) tiene un perfil de liberación que es adecuado para proporcionar API biodisponible y el perfil de liberación es estable con el tiempo (por ejemplo, bajo condiciones de almacenamiento) .
MX2017002596A 2014-08-28 2015-08-28 Composiciones y métodos farmacéuticos. MX2017002596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043349P 2014-08-28 2014-08-28
PCT/US2015/047556 WO2016033536A1 (en) 2014-08-28 2015-08-28 Pharmaceutical composition and methods

Publications (1)

Publication Number Publication Date
MX2017002596A true MX2017002596A (es) 2017-05-17

Family

ID=55400710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002596A MX2017002596A (es) 2014-08-28 2015-08-28 Composiciones y métodos farmacéuticos.

Country Status (12)

Country Link
US (4) US20160184324A1 (es)
EP (1) EP3185873A4 (es)
JP (2) JP2017529339A (es)
KR (1) KR20170056571A (es)
CN (1) CN106999502A (es)
AU (1) AU2015308614B2 (es)
BR (1) BR112017004127B1 (es)
CA (1) CA2994401A1 (es)
MX (1) MX2017002596A (es)
RU (1) RU2017110076A (es)
WO (1) WO2016033536A1 (es)
ZA (1) ZA201703398B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
JP2020500864A (ja) 2016-11-30 2020-01-16 リポカイン インコーポレーテッド 経口トリデカン酸テストステロン療法
CN109651851A (zh) * 2019-01-15 2019-04-19 上海崇明木棉花开手工社 天然植物来源的有机-无机杂化纳米颜料及制法和应用
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
CN114949939B (zh) * 2022-04-29 2023-10-03 广州安达净水材料有限公司 一种垃圾渗滤液蒸发用消泡剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
EP2985026B1 (en) * 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2007100614A2 (en) * 2006-02-24 2007-09-07 Scidose, Llc STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20130225544A1 (en) * 2009-01-08 2013-08-29 Lipocine Inc. Lipobalanced long chain testosterone esters for oral delivery
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions

Also Published As

Publication number Publication date
US20160184324A1 (en) 2016-06-30
AU2015308614A1 (en) 2017-04-20
KR20170056571A (ko) 2017-05-23
AU2015308614B2 (en) 2021-02-18
BR112017004127B1 (pt) 2023-04-11
RU2017110076A (ru) 2018-09-28
JP2017529339A (ja) 2017-10-05
ZA201703398B (en) 2019-01-30
JP2020193220A (ja) 2020-12-03
EP3185873A4 (en) 2018-05-02
BR112017004127A2 (pt) 2018-04-24
US20190269700A1 (en) 2019-09-05
US20200155575A1 (en) 2020-05-21
EP3185873A1 (en) 2017-07-05
RU2017110076A3 (es) 2019-02-25
US20180078568A1 (en) 2018-03-22
CN106999502A (zh) 2017-08-01
WO2016033536A1 (en) 2016-03-03
CA2994401A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
MX2017002596A (es) Composiciones y métodos farmacéuticos.
MX2018011278A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
CY1124104T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JP2015504924A5 (es)
De La Rubia et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
AR091006A1 (es) Formulaciones de testosterona proliposomal
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
MX2017010280A (es) Complejos de acetato de abiraterona, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
NZ718766A (en) Anti-folr1 immunoconjugate dosing regimens
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
JP2019530706A5 (es)
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
MX2022013450A (es) Formulaciones farmaceuticas.
MX2019001032A (es) Formulacion que tiene caracteristicas mejoradas de liberacion de farmacos ph dependientes, que contienen esomeprazol o una de sus sales farmaceuticas aceptable.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
EP4265298A3 (en) Salt
MX2015010594A (es) Esteres de testosterona de cadena larga lipobalanceados para suministro oral.
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
JP2016514706A5 (es)
PH12018500889A1 (en) Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine